SCHEMBL3757435

SCHEMBL3757435

CC(=O)c1ccc2c(c1)/C(=C/c1cc(Br)c(O)c(Br)c1)C(=O)N2

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 10/20 0.77
AURKA O14965 1/20 0.77
MAP1LC3B Q9GZQ8 3/20 0.68
LRRK2 Q5S007 3/20 0.68
PSEN1 P49768 1/20 0.68
PSEN2 P49810 1/20 0.68
APH1B Q8WW43 1/20 0.68
NCSTN Q92542 1/20 0.68
APH1A Q96BI3 1/20 0.68
PSENEN Q9NZ42 1/20 0.68
EGFR P00533 1/20 0.68
NTRK1 P04629 1/20 0.68
ARAF P10398 1/20 0.68
PIM1 P11309 1/20 0.68
BRAF P15056 1/20 0.68
CSNK2A1 P68400 1/20 0.68
PIM3 Q86V86 1/20 0.68
SIRT2 Q8IXJ6 1/20 0.68
SIRT1 Q96EB6 1/20 0.68
MYOC Q99972 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5775570 1.00 RAF1 (0.77) RAF1AURKAMAP1LC3BLRRK2PSEN1
SCHEMBL5773177 0.89 RAF1 (0.79) RAF1AURKAMAP1LC3BLRRK2PSEN1
SCHEMBL5773181 0.89 RAF1 (0.79) RAF1AURKAMAP1LC3BLRRK2PSEN1
SCHEMBL5774653 0.88 RAF1 (0.73) RAF1AURKAMAP1LC3BLRRK2PSEN1
Gw405841X SCHEMBL1395154 0.87 RAF1 (1.00) RAF1AURKAMAP1LC3BLRRK2PSEN1
Gw405841X SCHEMBL1395153 0.87 RAF1 (1.00) RAF1AURKAMAP1LC3BLRRK2PSEN1
SCHEMBL1394872 0.87 RAF1 (0.80) RAF1AURKAMAP1LC3BLRRK2PSEN1
SCHEMBL5080455 0.87 RAF1 (0.80) RAF1AURKAMAP1LC3BLRRK2PSEN1
SCHEMBL5773594 0.85 RAF1 (0.67) RAF1AURKALRRK2PSEN1PSEN2
SCHEMBL5773597 0.85 RAF1 (0.67) RAF1AURKALRRK2PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264494-A1 USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-10-22 US claimed
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-25 US disclosed
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-25 US disclosed
US-20090264494-A1 USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-10-22 US disclosed
EP-1003721-B1 BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES GLAXO GROUP LTD (GB) 2006-11-02 EP disclosed
US-6268391-B1 Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases GLAXO WELLCOME INC. 2001-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298376-A1 USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS NLN, HTT, PARK7 RAF1 3935/4885AURKA 2190/4885MAP1LC3B 187/4885
US-20090264494-A1 USE OF NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS NLN, BDNF, HTT RAF1 3617/4885AURKA 2377/4885MAP1LC3B 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.